RAPAMYCIN
MODERATE
▲ +4 papers · 7d
METFORMIN
MODERATE
▲ +2 papers · 7d
GLP-1 RA
STRONG
▲ +11 papers · 7d
SENOLYTICS
EMERGING
▼ −1 retraction
NMN
EMERGING
▲ +1 RCT · 7d
ACARBOSE
MODERATE
SGLT2i
STRONG
▲ +3 meta · 30d
RAPAMYCIN
MODERATE
▲ +4 papers · 7d
METFORMIN
MODERATE
▲ +2 papers · 7d
GLP-1 RA
STRONG
▲ +11 papers · 7d
SENOLYTICS
EMERGING
▼ −1 retraction
NMN
EMERGING
▲ +1 RCT · 7d
ACARBOSE
MODERATE
SGLT2i
STRONG
▲ +3 meta · 30d
Vol.
IV
· No.
19
Thursday, May 14, 2026
Issue:
Spring · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by
PubMed
·
CTG
·
Cochrane
Editorial team ·
geroevidence.com
Subscription ·
app.geroevidence.com
Home
Interventions
Evidence
Blog
About
Pricing
Sign in
Start free trial →
Geroevidence
·
Editorial desk
·
Evidence Analysis
Evidence Analysis
How to read the evidence — study design, bias, and interpretation.
1 article in this category
·
← All categories
§ Evidence Analysis · 1 article
NMN vs NR: comparing the evidence for the two main NAD+ precursors
A direct head-to-head comparison of every published human trial for NMN and NR — evidence rated honestly, and what the first head-to-head trial will tell us.
May 8, 2026 · 9 min read